Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
The STEP-1 data at 68 weeks showed sustained lipid benefits without attenuation, suggesting the changes persist as long as treatment continues 1
Patients should be counseled that some degree of hunger is normal and does not necessarily indicate treatment failure
The discussion examines which patients, particularly those with type 2 diabetes and cardiovascular risk, may benefit most, along with key limitations such as its exploratory design and gastrointestinal tolerability
10.1016/j.micpath.2017.08.038 148 SegainJ.-P.BltireD
US$ 27.45
US$ 27.92
US$ 29.77
US$ 22.85
US$ 23.58
US$ 27.28
